Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,497 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

NCT06821100
View directory record Official record
Conditions
Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination
Interventions
Thymalfasin (Thymosin alpha 1, Ta1)
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
65 Years to 100 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 4 Interventional Results available

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

NCT02814175
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
methotrexate (MTX), adalimumab (ADA)
Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Sun City, Arizona • Miami, Florida • Vernon Hills, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

NCT00027300
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
14
States / cities
Scottsdale, Arizona • Berkeley, California • Davis, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Minimally Processed Animal Protein on Biomarkers for Cognitive Decline

NCT06261775
View directory record Official record
Conditions
Healthy Lifestyle
Interventions
Red meat-based meal, No meat diet
Other
Lead sponsor
South Dakota State University
Other
Eligibility
65 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brookings, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 4 Interventional Results available

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

NCT00279201
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 79 Years
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
138
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Not applicable Interventional

Organizational Skills Interventions for Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01176136
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Homework, Organization, and Planning Skills (HOPS) Intervention
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

NCT01601236
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 23, 2026, 1:26 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Extended Release Protein Dosing

NCT07313436
View directory record Official record
Conditions
Nutrition
Interventions
Extended release nutritional protein, Control, Negative Dose
Other
Lead sponsor
VitaKey Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 23, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chronic Obstructive Pulmonary Disorder and Acute Exercise

NCT02780219
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
stable amino acid infusion, acute exercise with amino acid infusion, 24-hour post exercise amino acid infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 23, 2026, 1:26 AM EDT
Recruiting Phase 2Phase 3 Interventional

Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial

NCT06949228
View directory record Official record
Conditions
Ischemic Stroke, Acute Disease
Interventions
tenecteplase
Drug
Lead sponsor
ProMedica Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 4 Interventional Results available

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

NCT00351611
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Lyrica (pregabalin), placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
103
States / cities
Mobile, Alabama • Northport, Alabama • Tuscaloosa, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available

Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment

NCT01300728
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
NewGam 10% IVIG, Placebo
Drug · Other
Lead sponsor
Sutter Health
Other
Eligibility
50 Years to 84 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 23, 2026, 1:26 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

NCT01058642
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
ADL5747, Placebo, Pregabalin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 23, 2026, 1:26 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Tiragolumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Hot Springs, Arkansas • Clovis, California • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available

Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A

NCT01586819
View directory record Official record
Conditions
Wrinkles
Interventions
Botulinum Toxin, Chemical Peel Only
Drug · Procedure
Lead sponsor
Loyola University
Other
Eligibility
30 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
La Grange Park, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 23, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

NCT03977207
View directory record Official record
Conditions
Thyroid; Functional Disturbance, Hypothyroidism, Hemodialysis
Interventions
Levothyroxine Sodium, Placebos
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 23, 2026, 1:26 AM EDT
Active, not recruiting Not applicable Interventional

Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD

NCT04861571
View directory record Official record
Conditions
NAFLD
Interventions
Dietary intervention with very low calorie diet (VLCD), Control Arm
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Beverage Hydration Index: Assessment of Four Rehydration Solutions

NCT06272435
View directory record Official record
Conditions
Hydration
Interventions
Multiplier, Sugar Free, Sugar Free with Amino Acids, Water
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 23, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Oxalate-Driven Host Responses in Kidney Stone Disease

NCT05417568
View directory record Official record
Conditions
Kidney Stones
Interventions
Low Oxalate Diet, High Oxalate Diet
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults

NCT01157897
View directory record Official record
Conditions
Malaria, Plasmodium Vivax
Interventions
VMP001, P. vivax sporozoite challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 23, 2026, 1:26 AM EDT
Completed Phase 2 Interventional

A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

NCT01305824
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
PRT-201, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 23, 2026, 1:26 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Etanercept for the Treatment of Chronic Urticaria

NCT01030120
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
etanercept, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 23, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Immune Defense Protein Impact On Respiratory Immune Outcomes

NCT07431840
View directory record Official record
Conditions
Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions
Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo
Dietary Supplement
Lead sponsor
Quantec Ltd
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 1:26 AM EDT